Related Experiment Video

Updated: Aug 5, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Epigenetic Modulators and Immunotherapy in Malignant Melanoma

Ioannis Anestopoulos1, Sotiris Kyriakou1, Maria Deligiorgi2

  • 1Department of Cancer Genetics, Therapeutics & Ultrastructural Pathology, the Cyprus Institute of Neurology & Genetics, Nicosia, Cyprus.

Oncology Research
|July 25, 2026
PubMed

Insights

Epigenetic alterations drive melanoma progression and resistance to immunotherapy. Epigenetic drugs, combined with immune checkpoint inhibitors, show promise in overcoming this resistance and improving patient outcomes.

Area of Science:

  • Oncology
  • Immunology
  • Epigenetics

Background:

  • Melanoma mortality remains high despite targeted and immune therapies, largely due to drug resistance.
  • Epigenetic alterations, including DNA methylation and non-coding RNA changes, are implicated in melanoma development and therapeutic resistance.

Purpose of the Study:

  • To review the role of epigenetic mechanisms in melanoma progression and resistance to immunotherapy.
  • To explore the potential of epigenetic drugs in combination with immune checkpoint inhibitors to overcome drug resistance.

Main Methods:

  • Literature review of epigenetic mechanisms in melanoma.
  • Analysis of melanoma immune microenvironment and immunosuppressive factors.
  • Examination of drug resistance mechanisms related to epigenetic deregulation.
  • Evaluation of epigenetic drugs and emerging technologies for melanoma treatment.

Main Results:

  • Epigenetic dysregulation contributes significantly to melanoma pathophysiology and resistance to immune checkpoint inhibitors.
  • Epigenetic drugs can potentially reverse resistance to immune checkpoint inhibitors when used alone or in combination.
  • Emerging technologies like single-cell and spatial transcriptomics offer new avenues for clinical translation.

Conclusions:

  • Epigenetic modifications are critical drivers of melanoma progression and therapeutic resistance.
  • Combining epigenetic therapies with immune checkpoint inhibitors is a promising strategy to improve melanoma treatment outcomes.
  • Further research and technological advancements are needed for effective clinical implementation of epigenetic strategies in melanoma management.
Keywords:
DNA methyltransferase inhibitorsHistone Deacetylase inhibitorsMalignant melanomaepigeneticsimmune checkpoint inhibitorsimmunotherapy

More Related Videos

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

A 3D Organotypic Melanoma Spheroid Skin Model08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Epigenetic Regulation01:37

Epigenetic Regulation

Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
Epigenetic Regulation01:46

Epigenetic Regulation

Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...